RDGL
Neutral signalScored 2026-10-20 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
Research, not advice.
À propos
Vivos Inc.
- Nom
- Vivos Inc.
- Secteur
- Healthcare
- Industrie
- Medical - Devices
- Bourse
- OTC
- Capitalisation
- $20.8M
- Employés
- 1
- PDG
- Michael K. Korenko
- Site web
- https://www.radiogel.com
- Marché
- CATXITOCNVCRSRTS
Vivos Inc. is a medical technology company focused on radiation oncology, specializing in the development of internal radiation therapy devices for managing tumors that cannot be surgically removed. Their offerings include RadioGel, an injectable particle-gel that utilizes yttrium-90 for targeted radiation treatment of cancerous growths in both humans and animals. Additionally, the company provides IsoPet, a specific treatment for solid tumors found in animals. Established in 1994, Vivos Inc. is based in Richland, Washington. It previously operated under the name Advanced Medical Isotope Corporation before rebranding to Vivos Inc. in December 2017.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
ACHAT TOTAL: 200 000 titres (~99 600,00 $ US)
- Insiders
- Korenko Michael K
- Total bought
-
$99,600
Avg buy (VWAP, 90d window) $0.26 vs last close $0.04 (-83.3%)
- Total sold
-
—
Avg sell (VWAP, 90d window) —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-09-30
- Liquidity
- Illiquid $43,341/day · 20d vol
- Last synced
-
2026-10-26 21:10:54
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-30 | Korenko Michael K | Buy · P | 200,000 | $0.50 | $99,600 | Form 4 |
| 2026-09-16 | Weeks Brad Allan | Buy · P | 25,550 | $0.05 | $1,232 | Form 4 |
| 2026-08-10 | Korenko Michael K | Buy · P | 150,000 | $0.05 | $7,965 | Form 4 |
| 2026-08-10 | Weeks Brad Allan | Buy · P | 50,000 | $0.05 | $2,740 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-10-20 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
RDGL presents a single insider buy (~$99.6k) following a peer-reviewed publication on its PrecisionGel platform, which provides a modest event-driven signal, but the underlying financials are critically weak —…
The first sentence of the analysis written for RDGL on 2026-10-20 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Neutral signal
Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Unavailable or mixed. Current ratio 14.00 · operating margin -4629% — readings disagree
Suggested stop 0.04, nearest stored support minus 0.5 ATR(14.4% under the last close). Reward/risk to the next stored resistance is 1.23. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Recent news
- 2026-10-19 Vivos Therapeutics Closes Acquisition of Stake in SOD Sciences and 50% Interest in Pseudohypoxia Test, Opening a Potential Path to Access More Than 325,000 New Patients Through the AHA Channel Transaction Expected to Add More Than $10 Million to Stockholders'' Equity as Vivos Forms Strategic Alliances Offering Potential New Revenue and Profit Opportunities Transaction Expected to Add More Than $10 Million to Stockholders'' Equity as Vivos Forms Strategic Alliances Offering Potential New Revenue and Profit Opportunities
- 2026-10-15 Vivos Therapeutics Agrees to Acquire Minority Stake in SOD Sciences and 50% Interest in Proprietary Pseudohypoxia Test Transaction Expected to Increase Stockholders'' Equity; Opens Potential Collaboration Opportunities From New Strategic Alliances Transaction Expected to Increase Stockholders'' Equity; Opens Potential Collaboration Opportunities From New Strategic Alliances
- 2026-09-29 Vivos Therapeutics Reports Progress in Material Cost Reductions and Revenue Growth Initiatives Vivos Management is Executing on Plan to Immediately Reduce Overhead by an Estimated $3.6 million Annually While Also Driving Top-Line Revenue Vivos Management is Executing on Plan to Immediately Reduce Overhead by an Estimated $3.6 million Annually While Also Driving Top-Line Revenue
- 2026-09-08 Vivos Therapeutics Announces Material Debt Reduction LITTLETON, Colo., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or "the Company") (Nasdaq: VVOS), a medical device and healthcare services company focused on developing and commercializing diagnostic and treatment methods for patients with obstructive sleep apnea ("OSA") and other health conditions related to breathing and sleep disorders, today announced that on August 31, 2026, Vivos entered into twelve exchange agreements with Streeterville Capital, LLC, exchanging $2,861,270 of outstanding principal under its secured promissory note (the "Streeterville Note") for 11,445,080 shares of common stock at an exchange price of $0.25 per share.
- 2026-09-03 Vivos Inc. Announces Peer-Reviewed Publication Characterizing PrecisionGel™ Polymer Platform in Elsevier Journal of Drug Delivery Science and Technology Kennewick, WA, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company developing Precision Radionuclide Therapy™ (PRnT) for cancerous tumors in humans and animals, today announced the peer-reviewed publication of a paper describing the PrecisionGel™ thermogel polymer platform in the Journal of Drug Delivery Science and Technology.
- 2026-09-01 Vivos Therapeutics to Present at the 2026 Moody Capital Solutions Disruptive Growth & Life Sciences Conference Littleton, Colorado--(Newsfile Corp. - September 1, 2026) - Vivos Therapeutics, Inc. (NASDAQ: VVOS) ("Vivos" or the "Company"), a leading medical technology and healthcare services company focused on the diagnosis and treatment of obstructive sleep apnea (OSA) and related breathing and sleep disorders, today announced that Founder and Chief Executive Officer R. Kirk Huntsman will present at the 2026 Moody Capital Solutions Disruptive Growth & Life Sciences Conference, taking place September 9 and 10, 2026, at The Westin New York Grand Central in New York City.
- 2026-08-28 Vivos Therapeutics and South Palm Cardiovascular Associates Sign Definitive Agreements to Launch Regional Sleep Testing and Treatment Center LITTLETON, Colo., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or "the Company") (Nasdaq: VVOS), a leading medical device and healthcare services company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from obstructive sleep apnea ("OSA") and other health conditions related to breathing and sleep disorders, today announced the execution of definitive collaboration and operating agreements with South Palm Cardiovascular Associates, LLC ("SPCVA") to support the establishment and operation of a regional Sleep & Airway Medicine Center ("SAMC") in Palm Beach County, Florida.
- 2026-08-25 Vivos Therapeutics Reports Record New Patient Referrals at its Nevada Sleep & Airway Medicine Centers LITTLETON, Colo., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or “the Company”) (Nasdaq: VVOS), a leading medical device and healthcare services company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from obstructive sleep apnea (“OSA”) and other sleep disorders, today announced that new OSA patient referrals flowing into its Nevada Sleep & Airway Medicine Centers have increased 212% over the most recent six-week period versus the prior six-week period.
- 2026-08-20 Vivos Therapeutics Opens New Sleep Testing and Treatment Facility in Nevada to Meet Rapidly Growing Patient Demand for Sleep Apnea Testing and Treatment Vivos Therapeutics Opens New Sleep Testing and Treatment Facility in Nevada to Meet Rapidly Growing Patient Demand for Sleep Apnea Testing and Treatment
- 2026-08-18 Vivos Inc. Achieves Two Major Operational Milestones: First IsoPet® Shipments from New U.S. Production Facility and Authorization from India''s Nuclear Regulatory Authority for International Manufacturing Center Kennewick, WA, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company pioneering Precision Radionuclide Therapy™ (PRnT) for the treatment of cancerous tumors, today announced two significant operational milestones: the commencement of IsoPet® shipments from its new in-house U.S. production facility, and the receipt of authorization from The Atomic Energy Regulatory Board (AERB) of India, India''s national nuclear safety regulator, equivalent to the U.S. Nuclear Regulatory Commission, to proceed with an international manufacturing center in India. Together, these milestones establish Vivos as a dual-site global production organization for the first time in the Company''s history.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | -697.4% | -10.7% | -31.0% | 21.2% | 19.4% | |
| Ebit Margin | -4628.7% | -9301.7% | -14323.1% | -6898.8% | -16806.6% | |
| Ebitda Margin | -4628.1% | 1.4% | 0.7% | -0.7% | -1.4% | |
| Operating Profit Margin | -4628.7% | -9301.7% | -14323.1% | -6898.8% | -16806.6% | |
| Pretax Profit Margin | -4483.9% | -10394.7% | -14846.2% | -6767.3% | -16981.3% | |
| Continuous Operations Profit Margin | -4483.9% | -10394.7% | -14846.2% | -6767.3% | -16981.3% | |
| Net Profit Margin | -4483.9% | -10394.7% | -14846.2% | -6767.3% | -16981.3% | |
| Bottom Line Profit Margin | -4483.9% | -10394.7% | -14846.2% | -6767.3% | -16981.3% | |
| Current Ratio | 14.005 | 25.907 | 6.572 | 21.333 | 9.791 | |
| Quick Ratio | 13.519 | 25.907 | 6.572 | 21.333 | 9.791 | |
| Solvency Ratio | -14.828 | -3.545 | -0.416 | 0.585 | -0.157 | |
| Cash Ratio | 13.220 | 25.665 | 6.499 | 20.884 | 9.622 | |
| Price To Earnings Ratio | -10.132 | -16.183 | -9.269 | -6.435 | -10.872 | |
| Price To Earnings Growth Ratio | 2.398 | 1.803 | -0.711 | 0.558 | -0.134 | |
| Forward Price To Earnings Growth Ratio | 2.398 | 1.803 | -0.711 | 0.558 | -0.134 | |
| Price To Earnings Diluted Ratio | -10.132 | -16.183 | -9.269 | -6.435 | -10.872 | |
| Price To Earnings Diluted Growth Ratio | 2.398 | 1.803 | -0.711 | 0.558 | -0.134 | |
| Price To Book Ratio | 18.781 | 21.922 | 19.533 | 9.394 | 18.831 | |
| Price To Sales Ratio | 456.171 | 1,681.427 | 1,367.415 | 427.500 | 1,856.133 | |
| Price To Free Cash Flow Ratio | -14.435 | -27.952 | -20.622 | -13.931 | -28.670 | |
| Price To Operating Cash Flow Ratio | -15.159 | -27.952 | -20.622 | -13.931 | -28.670 | |
| Debt To Assets Ratio | 0.061 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Debt To Equity Ratio | 0.069 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Debt To Capital Ratio | 0.064 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long Term Debt To Capital Ratio | 0.051 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.124 | 1.040 | 1.179 | 1.049 | 1.114 | |
| Working Capital Turnover Ratio | 0.037 | 0.016 | 0.013 | 0.023 | 0.020 | |
| Operating Cash Flow Ratio | -17.454 | -19.534 | -5.278 | -13.711 | -5.774 | |
| Operating Cash Flow Sales Ratio | -30.093 | -60.155 | -66.309 | -30.687 | -64.742 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.050 | 1.000 | 1.000 | 1.000 | 1.000 | |
| Debt Service Coverage Ratio | -124.495 | 0.000 | 0.000 | 0.000 | -0.008 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | -98.601 | |
| Short Term Operating Cash Flow Coverage Ratio | -80.950 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -18.008 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Capital Expenditure Coverage Ratio | -19.942 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Dividend Paid And Capex Coverage Ratio | -19.942 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -9.400 | 116,820.298 | 171,728.182 | -55,367.527 | -128,842.211 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | -697.4% | ▼-686.7% | ▼-557.7% |
| Ebit Margin | -4628.7% | ▲4673.0% | ▲5763.1% |
| Ebitda Margin | -4628.1% | ▼-4629.5% | ▼-3702.5% |
| Operating Profit Margin | -4628.7% | ▲4673.0% | ▲5763.1% |
| Pretax Profit Margin | -4483.9% | ▲5910.9% | ▲6210.8% |
| Continuous Operations Profit Margin | -4483.9% | ▲5910.9% | ▲6210.8% |
| Net Profit Margin | -4483.9% | ▲5910.9% | ▲6210.8% |
| Bottom Line Profit Margin | -4483.9% | ▲5910.9% | ▲6210.8% |
| Current Ratio | 14.005 | ▼-11.902 | ▼-1.517 |
| Quick Ratio | 13.519 | ▼-12.388 | ▼-1.905 |
| Solvency Ratio | -14.828 | ▼-11.283 | ▼-11.156 |
| Cash Ratio | 13.220 | ▼-12.445 | ▼-1.958 |
| Price To Earnings Ratio | -10.132 | ▲6.051 | ▲0.446 |
| Price To Earnings Growth Ratio | 2.398 | ▲0.595 | ▲1.615 |
| Forward Price To Earnings Growth Ratio | 2.398 | ▲0.595 | ▲1.615 |
| Price To Earnings Diluted Ratio | -10.132 | ▲6.051 | ▲0.446 |
| Price To Earnings Diluted Growth Ratio | 2.398 | ▲0.595 | ▲1.615 |
| Price To Book Ratio | 18.781 | ▼-3.141 | ▲1.089 |
| Price To Sales Ratio | 456.171 | ▼-1225.255 | ▼-701.558 |
| Price To Free Cash Flow Ratio | -14.435 | ▲13.517 | ▲6.687 |
| Price To Operating Cash Flow Ratio | -15.159 | ▲12.793 | ▲6.108 |
| Debt To Assets Ratio | 0.061 | ▲0.061 | ▲0.049 |
| Debt To Equity Ratio | 0.069 | ▲0.069 | ▲0.055 |
| Debt To Capital Ratio | 0.064 | ▲0.064 | ▲0.051 |
| Long Term Debt To Capital Ratio | 0.051 | ▲0.051 | ▲0.041 |
| Financial Leverage Ratio | 1.125 | ▲0.084 | ▲0.023 |
| Working Capital Turnover Ratio | 0.037 | ▲0.021 | ▲0.015 |
| Operating Cash Flow Ratio | -17.454 | ▲2.080 | ▼-5.104 |
| Operating Cash Flow Sales Ratio | -30.093 | ▲30.062 | ▲20.304 |
| Free Cash Flow Operating Cash Flow Ratio | 1.050 | ▲0.050 | ▲0.040 |
| Debt Service Coverage Ratio | -124.495 | ▼-124.495 | ▼-99.595 |
| Interest Coverage Ratio | 0.000 | 0.000 | ▲19.720 |
| Short Term Operating Cash Flow Coverage Ratio | -80.950 | ▼-80.950 | ▼-64.760 |
| Operating Cash Flow Coverage Ratio | -18.008 | ▼-18.008 | ▼-14.406 |
| Capital Expenditure Coverage Ratio | -19.942 | ▼-19.942 | ▼-15.954 |
| Dividend Paid And Capex Coverage Ratio | -19.942 | ▼-19.942 | ▼-15.954 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -9.400 | ▼-116829.699 | ▼-20875.268 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $31.2M | $47.1M | $26.7M | $15.6M | $27.6M | |
| Enterprise value | $29.7M | $44.9M | $25.1M | $13.9M | $26.0M | |
| EV / Sales | 435.05x | 1602.39x | 1285.76x | 380.76x | 1748.24x | |
| EV / Op. cash flow | -14.46x | -26.64x | -19.39x | -12.41x | -27.00x | |
| EV / Free cash flow | -13.77x | -26.64x | -19.39x | -12.41x | -27.00x | |
| EV / EBITDA | -9.40x | 116820.30x | 171728.18x | -55367.53x | -128842.21x | |
| Net debt / EBITDA | 0.46x | -5761.84x | -10906.08x | 6797.07x | 7951.10x | |
| Current ratio | 14.01x | 25.91x | 6.57x | 21.33x | 9.79x | |
| Income quality | 0.67x | 0.58x | 0.45x | 0.45x | 0.38x | |
| Graham net-net | $0 | $0 | $0 | $0 | $0 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 96.9% | 111.8% | 103.7% | 98.1% | 101.0% | |
| Working capital | $1.5M | $2.1M | $1.4M | $1.7M | $1.5M | |
| Invested capital | $1.7M | $2.1M | $1.4M | $1.7M | $1.5M | |
| Return on assets | -164.2% | -130.3% | -179.8% | -141.7% | -154.7% | |
| Operating ROA | -154.4% | -135.5% | -166.6% | -149.1% | -194.6% | |
| Return on tangible assets | -164.2% | -130.3% | -179.8% | -141.7% | -154.7% | |
| Return on equity | -184.6% | -135.5% | -212.1% | -148.7% | -172.3% | |
| Return on invested capital | -178.3% | -121.3% | -204.6% | -151.6% | -170.5% | |
| Return on capital employed | -180.9% | -121.3% | -204.6% | -151.6% | -170.5% | |
| Earnings yield | -9.8% | -6.2% | -10.9% | -15.8% | -9.1% | |
| Free cash flow yield | -6.9% | -3.6% | -4.8% | -7.2% | -3.5% | |
| Capex / Op. cash flow | -5.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Capex / Depreciation | 27589.6% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Capex / Sales | 150.9% | 0.0% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 3416.2% | 8132.8% | 10535.4% | 5977.3% | 14897.8% | |
| R&D / Sales | 515.1% | 1159.6% | 3757.4% | 941.9% | 1926.8% | |
| Stock comp / Sales | 0.0% | 0.0% | 0.0% | 3820.9% | 10866.9% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 119d | 135d | 131d | 110d | 0d | |
| Days payables outstanding | 62d | 1016d | 3502d | 1036d | 5077d | |
| Operating cycle | 158d | 135d | 131d | 110d | 0d | |
| Cash conversion cycle | 96d | -881d | -3371d | -926d | -5077d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▼-33.7%EV / Sales ▼-72.8%EV / EBITDA ▼-100.0%EV / Op. cash flow ▲+12.181Earnings yield ▼-0.036
Profitability
Return on equity ▼-0.491Return on assets ▼-0.339Return on invested capital ▼-0.570Return on capital employed ▼-0.596Operating ROA ▼-0.189Income quality ▲+0.093Tax burden 0.000
Efficiency
Days sales outstanding ▼-15.430Days payables outstanding ▼-953.825Operating cycle ▲+22.900Cash conversion cycle ▲+976.725Capex / Sales n/aR&D / Sales ▼-6.445
Balance-sheet strength
Current ratio ▼-11.903Net debt / EBITDA ▲+5762.300Working capital ▼-614070.000Invested capital ▼-400556.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▲+12.9%EV / Sales ▼-75.1%EV / EBITDA ▲+100.0%EV / Op. cash flow ▲+12.546Earnings yield ▼-0.007
Profitability
Return on equity ▼-0.123Return on assets ▼-0.095Return on invested capital ▼-0.078Return on capital employed ▼-0.104Operating ROA ▲+0.402Income quality ▲+0.290Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding ▼-5015.093Operating cycle n/aCash conversion cycle ▲+5172.624Capex / Sales n/aR&D / Sales ▼-14.117
Balance-sheet strength
Current ratio ▲+4.214Net debt / EBITDA ▼-7950.648Working capital ▲+65794.000Invested capital ▲+279308.000Intangibles / Total assets n/a